Considerations in Multiple Myeloma: Health Economics

Supplements
Download PDF
Sagar Lonial, MD
Sandra E. Kurtin, RN, MS, AOCN, ANP-C
Jessica Freels, PharmD
Laureen Kenealy, PharmD
Jacob Kettle, PharmD
Casey Williams, PharmD, BCOP

This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: October 31st, 2008 - October 31st, 2009

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Target Audience
This educational publication is designed for physicians, nurses, and pharmacists who wish to enhance their knowledge concerning the health economics of multiple myeloma therapy.

Learning Objectives
At the completion of this activity participants should be able to:

  • Review the current epidemiology of multiple myeloma (MM)
  • Discuss the use of novel agents in the treatment of MM
  • Review the results of health economics data related to the use of these agents for the treatment of patients with MM


Disclosure Statement
In direct response to the September 2004 ACCME Standards for Commercial Support, CME Consultants issued a conflict of interest policy dated January 2, 2005. The policy states that the disclosure of potential financial conflicts of interest within the last 12 months must be made and resolved prior to the date of the CME/CE activity where commercial support grants are to be used to fund the activity. The following conflicts have been managed and resolved through CME Consultants Independent Review Committee. Our intent is to assist learners in assessing the potential for bias in information that is presented during the CME/CE activity. The faculty is also aware it is their responsibility to inform the audience if discussion of any non-FDA-approved uses of pharmaceutical, medical equipment, prostheses, etc will be included in their presentation.

Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

*Sandra Kurtin, RN, MS, AOCN, ANP-C has nothing to disclose.

Jessica Freels, PharmD's spouse's employer is Boehringer-Ingelheim.

Laureen Kenealy, PharmD has nothing to disclose.

Jacob Kettle, PharmD has nothing to disclose.

Casey Williams, PharmD, BCOP, is a consultant to Millennium and has received research support from Novartis.


*Content will include non-FDA-approved uses.

Disclaimer
The contents of some CME activities may contain discussion of off-label uses of some of the agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Related Items
Differentiating Novel Agents in the Management of Multiple Myeloma: Navigating the Role of the Oncology Pharmacist with Case Studies
Casey Williams, PharmD, BCOP, Leigh Casey, PharmD, Laure Dubois, PharmD
Supplements published on July 26, 2010
Considerations in Non-Hodgkin's Lymphoma: Clinical Trial Updates
André Goy, MD, MS, Amanda Copeland, MSN, RN, CNS, Anas Younes, MD, Sandra E. Kurtin, RN, MS, AOCN, ANP-C, Nelly G. Adel, PharmD, BCOP, BCPS
Supplements published on February 2, 2010
Considerations in Multiple Myeloma: Sequencing Strategies
Sagar Lonial, MD, Ajai Chari, MD, Sidney V. Keisner, PharmD, Sachin R. Shah, PharmD, BCOP
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: To Transplant or Not to Transplant...That Is the Question!
Sagar Lonial, MD, Joan Bladé, MD, Dareth N. Gilmore, MS, RN, CNP, Sandra Horowitz, PharmD, RPh
Supplements published on November 16, 2009
Considerations in Multiple Myeloma: Cytogenetic Testing
Sagar Lonial, MD, Steve Stricker, PharmD, MS
Supplements published on September 30, 2009
Considerations in Multiple Myeloma: Stem Cell Mobilization
Sagar Lonial, MD, William Bensinger, MD, Beth Faiman, RN, MSN, APRN, BC, AOCN
Supplements published on August 31, 2009
Considerations in Multiple Myeloma: Perspectives on Relevant End Points of Clinical Trials
Sagar Lonial, MD, Shaji Kumar, MD, Gail M. Sulski, RN, MS, FNP, AOCNP, Katherine Sanvidge Shah, PharmD, BCOP
Supplements published on July 14, 2009
Considerations in Multiple Myeloma: Do Complete Responses Correlate with Clinical Benefit?
Sagar Lonial, MD, Barbara B. Rogers, CRNP, MN, AOCN, ANP-BC, Jill M. Kolesar, PharmD, FCCP, BCPS
Supplements published on June 10, 2009
Considerations in Multiple Myeloma: Maintenance Therapy
Sagar Lonial, MD, Elizabeth Bilotti, MSN, APRN, BC, OCN®, Jonathan Kaufman, MD, Timothy McGuire, PharmD, FCCP, BCOP
Supplements published on May 11, 2009
Considerations in Multiple Myeloma: Retreatment Settings
Sagar Lonial, MD, Jeffrey Wolf, MD, Charise Gleason, MSN, ANP-BC, AOCNP, R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
Supplements published on March 31, 2009
Last modified: March 24, 2014